Status:

UNKNOWN

Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model

Lead Sponsor:

PD Dr. med. Volker Heinemann

Collaborating Sponsors:

MGO Ruhr-University Bochum (RUB)

Conditions:

Colo-rectal Cancer

RAS Wild-type

Eligibility:

All Genders

18+ years

Brief Summary

In this exploratory phase II trial, the possibility of a personalized treatment after resistance to cetuximab will be evaluated. Therefore, tumor material of all patients shall be obtained, transferre...

Eligibility Criteria

Inclusion

  • Male and female patients age ≥ 18 years
  • Written declaration of consent
  • ECOG Performance Status 0-1
  • Life expectancy\> 3 months
  • Histologically confirmed adenocarcinoma of the colon or rectum at stage UICC III or UICC IV
  • Histologically confirmed adenocarcinoma of the colon or rectum in stage UICC II with one of the following risk factors: CEA\> 200; T4 tumor, emergency surgery, \<12 distant lymph nodes, surgery due to intestinal obstruction (ileus)
  • Patient agrees to the preservation of tumor material for the purpose of molecular analyzes including the determination of the genetic profile of the tumor (participation in the project "RESIST")

Exclusion

  • Preoperative Radiotherapy
  • Preoperative chemotherapy
  • Heart failure\> Grade II (functional NYHA classification)
  • Existing concomitant disease or condition that would make the patient unsuitable for a study participation or interfere with the safety of the subject
  • Any psychological, familial, sociological or geographical event which does not allow observance of the study protocol
  • Additional carcinoma therapy (chemotherapy, radiation, biological therapy, immunotherapy or hormonal therapy) during the study
  • Known malignant second neoplasia within the last 5 years (except for a basal cell carcinoma or a carcinoma in situ of the uterine cervix).

Key Trial Info

Start Date :

January 1 2017

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

January 1 2025

Estimated Enrollment :

1000 Patients enrolled

Trial Details

Trial ID

NCT03263663

Start Date

January 1 2017

End Date

January 1 2025

Last Update

August 28 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Munich - Klinikum der Universitaet Muenchen

Munich, Bavaria, Germany, 81379